Candriam Luxembourg S.C.A. maintained its stake in CytomX Therapeutics, Inc. (NASDAQ:CTMX) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 195,000 shares of the biotechnology company’s stock at the end of the second quarter. Candriam Luxembourg S.C.A. owned 0.53% of CytomX Therapeutics worth $3,023,000 at the end of the most recent quarter.
A number of other hedge funds have also added to or reduced their stakes in CTMX. Hillsdale Investment Management Inc. acquired a new stake in CytomX Therapeutics during the first quarter worth approximately $159,000. Trexquant Investment LP raised its position in shares of CytomX Therapeutics by 260.8% in the first quarter. Trexquant Investment LP now owns 60,979 shares of the biotechnology company’s stock valued at $1,053,000 after buying an additional 44,079 shares during the period. TFS Capital LLC purchased a new position in shares of CytomX Therapeutics during the first quarter valued at about $247,000. Swiss National Bank raised its position in shares of CytomX Therapeutics by 19.1% in the first quarter. Swiss National Bank now owns 26,800 shares of the biotechnology company’s stock valued at $463,000 after buying an additional 4,300 shares during the period. Finally, Regents of The University of California raised its position in shares of CytomX Therapeutics by 48.1% in the first quarter. Regents of The University of California now owns 70,584 shares of the biotechnology company’s stock valued at $1,219,000 after buying an additional 22,918 shares during the period. 52.75% of the stock is owned by hedge funds and other institutional investors.
Shares of CytomX Therapeutics, Inc. (CTMX) traded down 3.63% during midday trading on Friday, reaching $13.53. 250,578 shares of the company’s stock traded hands. The stock’s market cap is $498.81 million. CytomX Therapeutics, Inc. has a 12 month low of $9.85 and a 12 month high of $20.02. The stock has a 50 day moving average of $14.54 and a 200-day moving average of $14.59.
A number of brokerages recently weighed in on CTMX. Jefferies Group LLC reaffirmed a “buy” rating and issued a $25.00 target price on shares of CytomX Therapeutics in a research note on Wednesday, April 26th. Zacks Investment Research raised shares of CytomX Therapeutics from a “hold” rating to a “buy” rating and set a $17.00 target price for the company in a research note on Wednesday, May 3rd. HC Wainwright reaffirmed a “buy” rating on shares of CytomX Therapeutics in a research note on Monday, May 8th. ValuEngine lowered shares of CytomX Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, May 11th. Finally, Cowen and Company reaffirmed a “buy” rating on shares of CytomX Therapeutics in a research note on Wednesday, June 28th. Two analysts have rated the stock with a sell rating, four have given a hold rating and five have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $25.60.
In other news, Director Frederick W. Gluck sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, June 26th. The shares were sold at an average price of $14.61, for a total value of $73,050.00. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Debanjan Ray sold 2,500 shares of the business’s stock in a transaction that occurred on Monday, July 3rd. The shares were sold at an average price of $15.47, for a total transaction of $38,675.00. Following the completion of the sale, the chief financial officer now directly owns 22,126 shares in the company, valued at approximately $342,289.22. The disclosure for this sale can be found here. In the last ninety days, insiders sold 39,343 shares of company stock worth $606,856. Insiders own 4.70% of the company’s stock.
CytomX Therapeutics Company Profile
CytomX Therapeutics, Inc is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies.
What are top analysts saying about CytomX Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for CytomX Therapeutics Inc. and related companies.